Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
BLFS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.10 - $29.55
Previous CloseN/A
Volume44.73K
Average Volume (3M)441.56K
Market Cap
$1.18B
Enterprise Value$971.62M
Total Cash (Recent Filing)$81.77M
Total Debt (Recent Filing)$23.82M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Nov 06, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding47,905,266
10 Day Avg. Volume364,533
30 Day Avg. Volume441,556
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)3.43
Price to Sales (P/S)14.54
P/FCF Ratio229.80
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue9.47
Enterprise Value/Gross Profit14.18
Enterprise Value/Ebitda-120.37
Forecast
1Y Price Target
$30.56Price Target Upside23.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBioLife Solutions achieved strong revenue growth, with a 29% increase year-over-year in the second quarter, exceeding projections.
Revenue GuidanceManagement raised the 2025 revenue guidance to $100-103M, indicating confidence in continued growth and performance.
Strategic AcquisitionsAcquisitions, such as the purchase of PanTHERA CryoSolutions, help solidify BioLife's leadership position in the biopreservation and cell and gene therapies market.
Bears Say
Gross MarginsGross margins fell a bit in the second quarter, to 62% from 64%.
BioLife Solutions News
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $19.10 and its highest was $29.55 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $1.18B.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is Nov 06, 2025 which is in 37 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on Aug 07, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.034 by -$0.296.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is -0.01.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 47,905,266 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.034. Following the earnings report the stock price went up 9.884%.
Which hedge fund is a major shareholder of BioLife Solutions?
Currently, no hedge funds are holding shares in BLFS
BioLife Solutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.56 (23.72% Upside)
$30.56 (23.72% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 301.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.19%
12-Months-Change
Fundamentals
Return on Equity
-5.98%
Trailing 12-Months
Asset Growth
3.27%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions (BLFS) is a leading provider of proprietary biopreservation tools and services for the cell and gene therapy sectors. The company specializes in the development and production of biopreservation media, cryopreservation solutions, and storage systems that ensure the viability and functionality of biologic materials during storage and transportation. Its core products include CryoStor, HypoThermosol, and other proprietary solutions designed to optimize the preservation of cellular therapies, tissue, and organs for transplantation.
BLFS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BioLife Solutions reported strong revenue growth and increased financial guidance, driven by cell processing revenue and strategic investments. However, increased operating expenses and a decrease in gross margin led to a higher net loss. Despite these challenges, the company's strong performance in revenue growth and strategic positioning suggest a positive outlook.View all BLFS earnings summariesBLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
BLFS Stock 12 Month Forecast
Average Price Target
$30.56
▲(23.72% Upside)
Technical Analysis
Azenta
―
Staar Surgical
―
Pulse Biosciences
―
Sanara MedTech
―
Kestra Medical Technologies Ltd.
―
Ownership Overview
19.86% Insiders
24.82% Mutual Funds
0.45% Other Institutional Investors
38.28% Public Companies and
Individual Investors